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Abstract. – OBJECTIVE: We developed a stan-
dardized technique for ultrasound guided intra-ar-
ticular injection of the hip joint with the purpose of
extending routine intra-articular injection of
hyaluronans and steroids to the hip, as commonly
used in the knee. In this article we report the safety
of this technique in an extended series of patients.
PATIENTS AND METHODS: Patients were in-
jected supine with an anterosuperior approach
under ultrasound guidance. The Us probe is ap-
plied with a target device for biopsy.
RESULTS: The standardised technique was
used to inject 1906 patients with 4002 injections
of hyaluronan products over a four-year period.
The treatment was well tolerated with few, and
exclusively local, side effects.
CONCLUSIONS: The administration of
hyaluronans under ultrasound-guided intra-ar-
ticular injection is a safe technique for treatment
of rheumatic diseases of the hip.
Key Words:
Intraarticular injection, Hip, Osteoarthritis, Safety,
Ultrasound.
Introduction
Intra-articular therapies are widely used. One
of the main advantages is that it allows therapeu-
tic agents to be given at their intended site of ac-
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tion. The original reports of intra-articular corti-
costeroids showed marked improvements in both
osteoarthritis and inflammatory arthritis, and to-
day most rheumatologists frequently use intra-ar-
ticular steroids. More recently trials of intra-ar-
ticular hyaluronans in knee osteoarthritis (OA)
also suggest positive benefits.
OA is the most common cause of joint pain in
the adult, particularly among the elderly1. It rep-
resents a major cause of morbidity, disability and
social isolation, especially when the hip and knee
are involved. Relief of pain with preservation or
restoration of joint motion is the major objective
of therapy. The revised American College of
Rheumatology (ARA) Guidelines for the man-
agement of knee and hip OA2, include intra-artic-
ular therapy (steroids and hyaluronate) as valu-
able additions to the therapeutic armamentarium
for the management of knee OA, such as arthro-
plasty and surgical joint replacement. Intra-artic-
ular hyaluronans (viscosupplementation), are in-
dicated in: (1) patients who have not responded
sufficiently to non-invasive, non-operative
modalities and who are not candidates for total
knee arthroplasty; (2) patients in whom nons-
teroidal anti-inflammatory drugs (NSAIDs) are
contraindicated (e.g. patients with a history of re-
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nal, hepatic or peptic-ulcer disease); (3) patients
intolerant to NSAID therapy; and (4) patients
who have failed to respond adequately to
NSAIDs and/or corticosteroids. The clinical effi-
cacy of viscosupplementation, in patients with
knee OA, has been documented in several ran-
domised, controlled, prospective trials3-8. The du-
ration of benefit of intra-articular hyaluronans
ranges from months to years.
The management of hip OA is similar to that
for the knee though the use of the intra-articular
therapies is more difficult. If the problems with
administration could be lessened then the intra-
articular steroids and viscosupplementation could
provide an additional weapon for the therapeutic
management of hip disorders. The intra-articular
injection of the hip is not as easy as for the knee,
mainly due to anatomical features of the joint
and the proximity of “sensitive” structures such
as the femoral artery and nerves. Even though in-
tra-articular hip injection may be performed
“blindly”, failure rate is significant. Leopold et
al9 injected fifteen human cadavers (30 hips) and
found that neither the anterior nor the lateral in-
jection approach, using published techniques
based on anatomic landmarks, were sufficiently
reliable to recommend for clinical use without
radiographic or sonographic guidance. The ante-
rior approach was successful in only 60% of in-
jections, while the lateral technique was success-
ful in 80% of injections. Moreover, when a slow-
ly-acting viscosupplement is used, the potential
local complications may jeopardize the therapeu-
tic benefit10. For such reasons, it has been sug-
gested that intra-articular injection of the hip
might be performed with an imaging guidance
(fluoroscopy, tomography, magnetic resonance
imaging or sonography). Fluoroscopic guidance
is preferred by some clinicians for hip aspiration
and injection, but this technique implies the use
of iodine contrast and radiation exposure for pa-
tients and physicians as well. Over the last few
years, the rapid technological advances in ultra-
sonography have greatly increased the potential
applications of sonographically-guided proce-
dures11. Sonographically-guided intralesional in-
jection is used as a rapid and reliable procedure,
especially in patients with arthritis, tenosynovi-
tis, and bursitis. After target localization, needle
placement can be performed under continuous
sonographic monitoring. Sonographic guidance
is particularly useful when the lesion is adjacent
to anatomic structures that could be seriously
damaged by a blind injection12.
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Ultrasound guidance in hip injection repre-
sents a safe, inexpensive and radiation-free tool
that allows identification and avoidance of vas-
cular and nervous structures and reliable, real-
time injection into the articular space13. This is
important as injection into the joint space is nec-
essary for efficacy and helps reduce the appear-
ance of local reactions.
We have standardized a technique for intra-ar-
ticular injection of the hip using ultrasound guid-
ance14-17 with the purpose of extending the use of
intra-articular therapies from the knee to the hip.
For such reason we also founded the ANTIAGE
non lucrative association (National Association
for Intra-Articular Therapy of Hip Joint,
www.antiagefbf.it), that is made up of physicians
specialized in different medical fields such as In-
ternal Medicine, Radiology, Rheumatology,
Physical Medicine, Sports Medicine, interested
in treating the various hip diseases with ultra-
sound-guided intra-articular injections. All spe-
cialists adhered to set up a national Italian reg-
istry of all the ultrasound-guided intra-articular
injections performed in accordance with the stan-
dardized technique. In this registry are recorded
the patients distinguishing characteristics, their
different hip diseases, the drugs used, the side ef-
fects, the assessment of the treatment effective-
ness, the treatment courses and the total number
of injections. Objective of this study was to as-
sess safety profile for intra-articular ultrasound-
guided hip injection with hyaluronic acid prod-
ucts performed in 9 different rheumatology or or-
thopaedic centers who administered such therapy
following our standardized technique. We report
the safety data from four years of activity.
Patients and Methods
Ultrasound guided injection technique: all pa-
tients were examined supine with the hip in inter-
nal-rotation of 15-20°. A 7 MHz linear or 3.5
MHz convex transducer (ASTRO 256, Hitachi-
Esaote, Genoa, Italy) was used together with a
sterile bioptical target device. The hip joint was
scanned by means of an anterior parasagittal ap-
proach, lateral to the femoral vessels. The trans-
ducer was aligned with the long axis of the
femoral neck, comprising also the acetabulum and
the femoral head. Intra-articular (IA) injection was
performed by inserting into the biopsy guide a 20
gauge (9 cm) spinal needle with the anterosuperior
approach. Then, using biopsy real-time guidance
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software, the needle was advanced into the anteri-
or capsular recess, at the level of the femoral head.
Once the needle came into contact with the
femoral head, the needle was retracted 1mm. Then
the treatment was injected into the hip joint and
verification of intra-articular placement was evi-
dent with the real-time monitoring (direct visual-
ization of viscous fluid or air bubbles) also utilis-
ing power Doppler imaging (flow signals in intra-
articular recess). The colour Doppler vision al-
lowed us to avoid injecting blood vessels.
Patients Selection
This is a multicentric retrospective study re-
garding the safety of US-guided Intra-articular
injection of hyaluronic acid in hip joint in pa-
tients affected by hip osteoarthritis.
Inclusion Criteria
Patients attending to our Ambulatory for hip
pain in the years going from 2005 to 2008 that
had mono or bilateral symptomatic hip OA ac-
cording to ARA criteria18, refractory to therapy,
with radiological OA graded II-IV (Kellgren and
Lawrence)19 assessed within the two preceding
months. Exclusion criteria included use of anti-
coagulant therapy (to avoid the possibility of in-
tra-articular or pericapsular haemorrhages). Usu-
ally, the absence of articular space at radiological
examination represents an exclusion criteria for
patients candidates for intra-articular hip injec-
tion, as surgical interventions are best suited for
such patients. Although a recent review of 80 pa-
tients with symptomatic knee OA treated with
hyaluronic acid revealed that patients with a
complete collapse of joint space or bone loss
showed a poor clinical response20, the absence of
articular space at radiological or ultrasound as-
sessment was not considered as an exclusion cri-
teria for the analysis when patients were unable
to undergo to surgical intervention or hip arthro-
plasty. Even if it is not a grade with primary indi-
cation to viscosupplementation, in some cases in-
tra-articular treatment may support a temporary,
even if small, symptoms’ relief. In this cases, ul-
trasound-guided hip injection was performed as a
second line option with the aim of possibly re-
ducing pain and NSAIDs consumption. For such
reason, safety data reported in this study include
data from IV Kellgren-Lawrence IV grade pa-
tients as well. Injections were given according to
symptoms and clinical judgment; namely one or
two injections every six months according to pa-
tients’ clinical condition. One 2 ml ampule was
used with high molecular weight HA, e.g. Syn-
visc and Euflexxa; two 2 ml ampule with low or
medium molecular weight HA, e.g. Hyalgan,
Hyalubrix, Jointex, and Ortoial.
Safety was evaluated by recording adverse
events reported during the follow-up period. All
patients were evaluated at baseline and at each
control visit, performed every 3 months. All pa-
tients also received a phone call every 3 months
from nurses attending to Rheumatology Units
where the study was performed, in order to pro-
gram next step (control visit or hip injection) and
also to screen drop-out from programmed thera-
py and eventual motivations for dropping out.
All patients who decided to withdraw from pro-
grammed therapy were interviewed and eventual
adverse events (AE) were recorded.
All adverse events/effects were studied and
collected in subgroups related to: HA used, radi-
ological grading of osteoarthritis according to
Kellegren-Lawrence classification, patients’ age,
algofunctional Lequesne21 score at the basal eval-
uation arranged by low, medium and high grade.
A rank testing was performed between different
rates of adverse events or side effects occurrence
and patient’s mentioned subgroups.
Adverse events were recorded by a direct in-
terview of patients that was performed when pa-
tients were visited at each control visit. Patients
were intensively studied for eventual side effects
such as pain or other side effects such as hip joint
or other joints swelling, fatigue, fever, dermato-
logical or respiratory affections that may be re-
lated to HA injection.
Statistical Analysis
In order to describe patients evaluated in this
study, descriptive statistics were reported as appro-
priate. Mean, range and numerousness were report-
ed for continuous variables, count and proportions
were reported for discrete variables. Rates of AEs
in different subpopulations were analyzed by a chi-
square test. Significant independent variables were
selected among some presumed predictive indices
using a backward stepwise method. p < 0.05 was
considered statistically significant.
Results
1906 patients received 4002 injections.Pa-
tients’ demographics are shown in Table I.
Different hyaluronic acid products and their
characteristics are shown in Table II.
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Table III shows the number of patients and the
number of injections with each HA product.
Figure 1 summarizes the number of patients
per different injections numbers.
No systemic side effects or joint infections
were observed in our study. A transient sensation
of local heaviness and pain was reported. Gener-
ally these reactions lasted from 1 to 4 days. By
63% of patients lasting from few hours to one
day, by 17% from one to four days and by 20%
from four to ten days. No differences were ob-
served when comparing different rates of side ef-
fects in populations receiving different hyaluron-
ic acid products, thus suggesting that, in terms of
safety, different products may have similar safety
profiles in the selected patients. Rates of painful
events arranged by Kellgren-Lawrence radiologi-
cal score were higher in the 1° and 4° degree as
shown in table 4 but no statistical significance
was obtained when comparing rates from differ-
ent groups categorized for Kellgren-Lawrence
radiological score. Table V shows that the higher
rate of painful events arranged by age was no-
ticed by patients in their fifties (5.17%), while
the lower by patients in their seventies (1.33%),
but still no significative differences were ob-
served.
Table VI shows that the lower rate of painful
events arranged by Lequesne score was dis-
played in the higher degree of the score, but still
no significative differences were observed.
A modest ecchymosis at the site of injection
was reported by 6.3% of the injections (264
events)
In all cases direct visualization of needle intro-
duction and progression into the articular space
was by on-screen guidance. The visualization of
the products injected varied depending on their
density and molecular weight. Higher molecular
weight products, like Synvisc or Euflexxa, dis-
played a characteristic ultrasound pattern show-
ing a little hyperechogenic cloud inside the joint
whereas lower molecular weigth HA, like Hyal-
gan, were detected only indirectly through the
Parameter Summary statistic All patients
Number of patients N 1.906
Gender
Male N (%) 1.011 (53)
Female N (%) 895 (47)
Age Mean (SD) 63.4 (11.4)
Weight (kg) Mean (SD) 74.6 (13.5)
Height (cm) Mean (SD) 167 (9)
Body mass index (kg/m2) Mean (SD) 26.5 (3.8)
OA location
Right hip % 40.5
Left hip % 38.2
Bilateral % 21.3
OA disease severity
Grade II (%) 801 (42)
Grade III (%) 878 (46)




Table I. Features of different hyaluronic acid products.
Trade name Molecular weight Source mg/ml
Hyalgan 500-730 KDa HA extracted from rooster combs 20 mg/2 ml
Hyalubrix > 1500 KDa HA produced by fermentation from bacteria 30 mg/2 ml
Jointex 800-1200 KDa HA produced by fermentation from bacteria 16 mg/2 ml
Synvisc 6000 KDa HA extracted from rooster combs 16 mg/2 ml
Euflexxa 2.4-3.6 million Da HA produced by fermentation from bacteria 20 mg/2 ml
Intragel 1 million Da HA produced by fermentation from bacteria 16 mg/2 ml
Table II. Features of different hyaluronic acid products.
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amplification of the articular space. The time tak-
en to complete the procedure varied between 7
and 10 minutes.
None of the reactions caused loss of daily ac-
tivity or required treatment.
After treatment, four patients (< 0.1%, 1 re-
ceiving Synvisc, 1 receiving Euflexxa, 1 receiv-
ing Hyalubrix and 1 receiving Jointex) showed a
rapid symptomatic worsening with local pain in-
tensification. Pain didn’t show any more me-
chanical characteristics and became continuous,
during day and night, and lasted for over 10
days. Due to persisting symptoms, all patients
underwent to a magnetic resonance imaging
(MRI) of the symptomatic hip, and in each of
these patient MRI demonstrated femur head bone
oedema. After treatment with intra-muscular
Clodronate all patients reported slow but contin-
uous remission of symptoms until complete reso-
lution in two months with restitutio ad integrum.
It was impossible for us to identify predictor fac-
tors such as age, gender or radiological grade or
used product that could lead to such event.
Discussion
Published data on viscosupplementation in the
OA hip is limited13. Recent clinical evidence has
shown that intra-articular injection with hyaluro-
nians may be a safe and effective treatment to
improve functionality and to reduce pain in pa-
tients with hip OA13.
Our technique uses an anterosuperior access
while that of Qvistgaard et al12 uses an anteroinferi-
or approach. The latter is commonly used for the
arthrocentesis. The needle position in the lower part
of the joint allows better drainage of the effusion.
However, we believe that the anterosuperior ap-
proach is better due to positioning the medical
Number Number Patients Injections Number
Trade of of with painful with painful of painful
name patients injections events (%) events (%) events
Hyalgan 168 314 4.1 2.22 7
Hyalubrix 377 862 6.8 3.01 26
Jointex 224 407 4.9 2.7 11
Synvisc 950 2146 8.8 3.58 77
Ortoial 127 205 4.7 2.92 6
Euflexxa 60 68 3.3 2.94 2
Total 1906 4002 7.5 3.2 129
Table III. Injections number for each hyaluronic acid product and related painful events (%).
Figure 1. Number of patients
and the number of injections
with each HA product.
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product just above the femoral head which exploits
gravity to involve the articular cartilage of the
femoral head and acetabulum. With an inferior in-
jection approach the medical product is placed at
the base of the femoral head on the femoral neck.
We used a bioptic device attached to the probe for
simpler, faster and more accurate needle position-
ing compared with the free-hand US guidance. Spe-
cific bioptic guidance software allowed real time
monitoring of needle introduction and intra-articu-
lar placement producing a good visualization of the
needle during the procedure and reducing the time
of injection and patients’discomfort as well.
The side effects seen after hip injection are
similar to those found in patients treated with
knee injections22,23.
Our four years experience of intra-articular
ultrasound-guided treatment of the hip suggests
that it can be as safe and reliable as that used for
knee diseases, that is commonly performed with-
out image-guidance. The safety data confirm
good systemic tolerance, as already documented
with knee injection. Differently from fluoroscop-
ic guidance, ultrasound-guidance allows the de-
tection of arteries and veins via colour-Doppler
signal and also allows the detection of nerves,
granting a more safe needle introduction. Aim of
this investigation was to assess safety for image-
guidance performed by ultrasound and these data
seem to confirm the relevance of ultrasound
guidance to recognize and consequently avoid
sensitive structures such as vessels and nerves.
The most severe adverse event in our cases was
Bone Marrow Edema Syndrome (BMES) that
was reported in 4 patients, for an evaluated
prevalence of 0.1% in our population. BMES
% rate per % rate per
Basal lequesne Patients Injections patients injections Cases Statistical
score number number number number number significance
Under 40 51 91 8.33 4.91 4 NS
40-49 159 209 6.73 3.27 7 NS
50-59 349 840 10 5.17 43 NS
60-69 455 1016 6.05 2.67 27 NS
70-79 571 1242 2.4 1.33 17 NS
over 80 316 604 2 0.80 5 NS
Total 1906 4002 2.45 103
Table V. Rates of painful events arranged by age groups. Statistical significance was evaluated by ANOVA testing between
each group and every other group.
KL % rate per % rate per
radiological Patients Injections patients injections Cases Statistical
scale number number number number number significance
1° 127 255 11.11 6.84 17 NS
2° 695 1209 8.81 5.48 66 NS
3° 733 1166 4.5 2.89 34 NS
4° 349 425 11.11 8.16 35 NS
Total 1906 4002 3.61 152
Table IV. Rates of painful events arranged by Kellgren-Lawrence radiological score. Statistical significance was evaluated by
ANOVA testing between each group and every other group.
Basal lequesne Patients Injections Patients Injections Cases Statistical
score number number % rate % rate number significance
Low (0-5) 791 1557 8.43 3.18 50 NS
Medium (6-10) 498 957 8.25 3.61 35 NS
High (11+) 617 1488 3.56 2 30 NS
Total 1906 4002 2.73 115
Table VI. Rates of painful events arranged by low, medium and high Lequesne score. Statistical significance was evaluated
by ANOVA testing between each group and every other group.
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refers to a transient clinical condition with un-
known pathogenic mechanisms. Many hypothe-
ses have been previously proposed in order to ex-
plain the pathogenesis of the disease. Unfortu-
nately, at now, the etiology of BMES remains
obscure24. A reflex sympathetic mechanism
could be the primary mechanism leading to
BMES but further studies are needed to confirm
such hypothesis.
The local tolerance was also good, with mild
side effects following 2.2% of Hyalgan injec-
tions and 3.5% with Synvisc. In the latter the in-
creased percentage of painful events may be due
to the higher molecular weight of this product.
Related to Kellgren-Lawrence radiological
score the higher number of painful events by pa-
tients with 1° and 4° degree may be due to the
lack of symptoms in the first group and to the
oversensibility of the patients in the second one.
A reduced susceptibility to pain may cause the
smaller frequency of painful events in the older
population and in the more severe Lequesne
score as well.
Patients’ daily activities were unaffected by
these events. No septic complications were ob-
served. No increased effect of repeated injections
or cycles of injections was detected.
The aforementioned data are similar to those
already reported in our previous papers14-17.
No increased effect of repeated injections or
cycles of injections was detected.
The injection of 4 ml (2 ampoules at the same
time) is well tolerated as 2 ml (1 ampoule). That
means the reduction in the number of injections
performed and consequently in the occurrence of
possible side effects, in the medical expenses and
in a sparing of time for the patients and the doc-
tors as well. The results confirm the safety and the
precision of the technique. Direct evidence of the
needle placement and direct or indirect evidence
of the therapeutic fluid inside the joint are very
important goals. Ultrasound guidance is more eco-
nomic and faster in comparison to the computed
tomography (CT) or fluoroscopic guidance. Con-
trary to CT or fluoroscopic techniques ultrasound
does not require use of contrast, allowing use in
patients intolerant to iodized contrasts. It can be
repeated without problems of radiation load to ei-
ther the operator or the patient.
Moreover, the European Community “Direc-
tive 97/43/Euratom” lays down the general prin-
ciples for protection of individuals in relation to
the exposure of patients to radiation as part of
their medical diagnosis or treatment. It requires a
sufficient net benefit, weighing the total potential
therapeutic benefits against the individual detri-
ment that the exposure might cause, taking into
account the efficacy, benefits and risks of avail-
able alternative techniques having the same ob-
jective but involving no or less exposure to ioniz-
ing radiation. Existing types of practices involv-
ing medical exposure may be reviewed whenever
new, important evidence about their efficacy or
consequences is acquired. If exposure cannot be
justified, it should be prohibited.
Conclusions
We believe that, even if fluoroscopy or CT
guidance can, on occasion, be justified, neverthe-
less for general and repetitive use physicians
should use the ultrasound technique that elimi-
nates use of radiation and is cost-saving. The
technique has proved well tolerated, despite the
advanced age of the patients and the high clinical
and radiological degree of disease in some cases.
The horizon of loco-regional therapy in rheumat-
ic hip disease appears to be extremely promising.
The ultrasound guided hip injection technique
can allow to extend to the hip what is common-
place for the knee joint in OA and other rheumat-
ic diseases.
This is not a placebo controlled study and is
based upon data on the safety profiles obtained
from cohorts of patients undergoing to different
hyaluronans injections into hip joint performed
with a standardized technique in different Italian
centres. Moreover, patients assumed different
kinds of pain killers and/or NSAIDs, and at dif-
ferent dosages: for such reason, mild to moderate
pain adverse events may have been altered in
their perception depending on the type and
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